RNA sequencing of nanatinostat treated EBV-associated gastric cancer cell line
A recent clinical study demonstrated that the combination of an orally administered histone deacetylase (HDAC) inhibitor, nanatinostat (NSTAT) with valgancicovir (GCV), showed activity as a promising lytic induction therapy for EBV-positive lymphoma. In this study, we evaluated the lytic induction activity of NSTAT and the therapeutic efficacy of NSTAT-based lytic induction therapy in two representative EBVaGC cell lines both in vitro and in vivo. We found that NSTAT efficiently induced the reactivation of EBV immediate early, early and late genes in EBVaGC cell lines.